- Home
- WD vs GLUE Comparison
WD vs GLUE Comparison
Compare WD & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WD | GLUE |
|---|---|---|
| Founded | 1937 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WD | GLUE |
|---|---|---|
| Price | $50.95 | $18.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $76.00 | $32.00 |
| AVG Volume (30 Days) | 271.2K | ★ 904.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,234,306,000.00 | $123,672,000.00 |
| Revenue This Year | $20.60 | N/A |
| Revenue Next Year | $7.79 | $2.45 |
| P/E Ratio | $111.48 | ★ $72.42 |
| Revenue Growth | 8.99 | ★ 63.54 |
| 52 Week Low | $42.12 | $4.12 |
| 52 Week High | $90.00 | $25.77 |
Technical Indicators
Market Signals| Indicator | WD | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 51.65 |
| Support Level | $47.77 | $17.07 |
| Resistance Level | $52.44 | $18.66 |
| Average True Range (ATR) | 2.21 | 1.20 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 60.18 | 58.67 |
Price Performance
Historical ComparisonAbout WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).